JUL 9, 2026 · JOURNAL ARTICLE
T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2.
Human Vaccines & Immunotherapeutics
A mechanistic study using genetically modified mouse models demonstrating that T cell-associated immunity from a heterologous rBCG/protein vaccine confers cross-variant protection against SARS-CoV-2 JN.1, with clear immunological endpoints but limited to preclinical animal models.
Reported
Study population6- to 8-week-old K18-hACE2 mice and knockou…